Related Experiment Video
Updated: Aug 16, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[Transrectal prostatic biopsy management policy for patients older than 50 years in relation to PSA values elaborated
Daniel Santos Arrontes1, Ignacio Cortés Aránguez, Francisco Begara Morillas
1Servicio de Urología, Hospital Santa Bárbara, Ciudad Real, España. danielsantosarrontes@yahoo.es
Objectives:
To decide the action politics (to perform or not transrectal prostatic biopsy) for a PSA cut point of 4 and 10 ng/ml through the construction of a mathematical decision tree.
Methods:
We calculate the usefulness of the biopsy through a subjective score, from 0 to 10, established after a survey of the 20 staff members of the health-care area, applying an global analysis with creation of total profile cards through an orthogonal design.
Results:
The main usefulness of prostate cancer screening would be not to perform transrectal prostatic biopsies when PSA is lower than 4 ng/ml.
